KIR3DL3 CRISPR/Cas9 KO Plasmid (h): sc-406227

Overview

KIR3DL3 encodes an inhibitory killer cell immunoglobulin-like receptor expressed on subsets of NK cells and T cells, where it contributes to immune surveillance by dampening cytotoxicity and cytokine release through ITIM-dependent recruitment of phosphatases such as SHP-1/2. By modulating signaling downstream of activating receptors, KIR3DL3 helps tune the balance between immune activation and tolerance, influencing pathways that govern lymphocyte effector function and target-cell recognition. Variation in KIR gene content and expression is frequently studied in the context of HLA-dependent immune interactions, with implications for tumor immunology, antiviral responses, and transplant immunobiology. Dysregulated inhibitory receptor signaling can alter immune set points in chronic infection, autoimmunity, and cancer-associated immune evasion, making KIR3DL3 a useful target for mechanistic studies of inhibitory checkpoint-like regulation in innate and innate-like lymphocytes.

KIR3DL3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KIR3DL3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KIR3DL3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KIR3DL3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KIR3DL3 protein expression.

This CRISPR knockout system enables efficient generation of KIR3DL3-deficient cell models for investigation of KIR3DL3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting KIR3DL3 exon(s) critical for KIR3DL3 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple KIR3DL3 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by KIR3DL3 CRISPR/Cas9 KO Plasmid (h) and KIR3DL3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KIR3DL3 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by KIR3DL3 HDR Plasmid (h) and KIR3DL3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KIR3DL3 homology arms to support homology-directed repair at defined KIR3DL3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.